Drugs / DA-302168S
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06541730 | Aug 2024 → Jan 2025 | morbid obesity | Chendu DIAO Pharmaceutical Group CO., LTD. | Completed | No outcome recorded |
| Phase 1 | NCT06534346 | Jul → Aug 2024 | — | Chendu DIAO Pharmaceutical Group CO., LTD. | Completed | No outcome recorded |
| Phase 1 | NCT06534320 | Apr → Dec 2024 | morbid obesity | Chendu DIAO Pharmaceutical Group CO., LTD. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06953063 | May → Dec 2025 | — | Chendu DIAO Pharmaceutical Group CO., LTD. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07629544 Comparator | Jun 2026 → Jul 2027 expected | — | Chendu DIAO Pharmaceutical Group CO., LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DA-302168S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06534346 ↗ |
| Action | Activate | “A small molecule GLP-1R agonist tablet, orally administration, once daily，16weeks.” NCT06953063 ↗ |
| Modality | Small molecule | “A small molecule GLP-1R agonist tablet, orally administration, once daily，16weeks.” NCT06953063 ↗ |
| Route | Oral | “Single Oral DA-302168S Tablet” NCT06534346 ↗ |